PARP-1/HDAC-IN-1

Cat. No.:	HY-146160
CAS No.:	3032621-10-3
Molecular Formula:	$C_{22}H_{18}N_4O_4$
Molecular Weight:	402.4
Target:	PARP; HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PARP-1/HDAC-IN-1 is a PARP-1/HDAC6 dual targeting inhibitor with IC_{50}s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities[1].			
IC_{50} & Target	PARP-1 68.90 nM (IC_{50})	HDAC6 510 nM (IC_{50})	HDAC2 42130 nM (IC_{50})	HDAC3 7220 nM (IC_{50})
In Vitro	PARP-1/HDAC-IN-1 (Compound 1–8-6) possesses potent inhibitory activity against MDA-MB-436, ES-2, DU145, A549, HCC1937, and Capan-1 cells with IC_{50} values of 0.35 μM, 1.16 μM, 3.38 μM, 5.67 μM, 2.85 μM, and 4.53 μM, respectively[1]. PARP-1/HDAC-IN-1 (Compound 1–8-6; 0.3-10 μM) is able to heighten expression level of acetylated α-tubulin with marginal effects to acetylated histones H3 and H4[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Ziwei Chi, et al. Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors. Bioorg Med Chem Lett. 2022 Sep 1;71:128821.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA